Css LLC Cel Sci Corp Call Options Transaction History

Css LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Nov 15, 2021	SELL	$7.64 - $12.49 $158,912 - $259,792	-20,800 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $180,544 - $571,792	20,800 New	20,800 $181,000
Q1 2021 May 17, 2021	SELL	$12.0 - $27.64 $146,400 - $337,208	-12,200 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$11.05 - $16.62 $300,560 - $452,064	-27,200 Reduced 69.04%	12,200 $143,000
Q3 2020 Nov 16, 2020	BUY	$11.69 - $14.54 $162,491 - $202,106	13,900 Added 54.51%	39,400 $502,000
Q2 2020 Aug 14, 2020	BUY	$9.75 - $17.6 $248,625 - $448,800	25,500 New	25,500 $380,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.